If CIPA results from loss-of-function mutations in the NTRK1 gene encoding TrkA, then molecular treatment involving a receptor tyrosine kinase for NGF would be the most effective therapeutic technique. Here, NTRK1 is linked to hereditary sensory and autonomic neuropathy type 4.